COVID-19 Infections and Vaccines Causes Elevation of Amyloid Precursor Protein Which Contributes to Persistent Headaches

Medical News: As we continue to understand the long-term effects of COVID-19 and its vaccines, new research is shedding light on the connection between these events and persistent headaches. Many people have reported ongoing headaches after recovering from COVID-19 or receiving a vaccine. These headaches, unlike typical headaches, can persist for months and significantly impact daily life. But what could be the underlying cause?


COVID-19 Infections and Vaccines Causes Elevation of Amyloid Precursor
Protein Which Contributes to Persistent Headaches
Image: AI-Generated

A groundbreaking study conducted by a team of Norwegian and international researchers suggests a potential link between these headaches and changes in the levels of certain proteins in the brain, including the Amyloid Precursor Protein (APP). These findings open up new avenues for understanding the mechanisms behind post-COVID-19 and vaccine-related headaches, potentially contributing to better treatments and prevention methods.
 
The Study and Its Purpose
The study was carried out by researchers from Oslo University Hospital, the Norwegian University of Science and Technology, and other prominent institutions. They set out to investigate why some individuals experience persistent headaches following COVID-19 infection or vaccination. The researchers specifically focused on measuring levels of several proteins that are known to play a role in brain function and inflammation, including Amyloid Precursor Protein (APP), Pregnancy Zone Protein (PZP), Cathepsin L1 (CTSL), and Serum Amyloid A (SAA1).
 
Their goal was to determine if these protein levels were altered in individuals suffering from long-lasting headaches post-COVID-19 or vaccination. By comparing these patients to healthy controls, they hoped to identify potential biomarkers and shed light on the biological mechanisms that contribute to these debilitating headaches.
 
This Medical News report delves deeper into the study, aiming to explain these findings in a way that is easy to understand, even for those without a medical background.
 
Key Findings: Elevated Amyloid Precursor Protein and More
One of the most significant findings from the study is the strong and persistent upregulation of Amyloid Precursor Protein (APP) in patients who reported headaches after recovering from COVID-19. APP is a protein typically associated with Alzheimer's disease, where it plays a role in the formation of amyloid plaques in the brain. However, its elevation in patients with post-COVID-19 headaches suggests it may also be involved in the development of these persistent headaches.
 
The researchers found that patients who experienced headaches after COVID-19 had consistently higher levels of APP compared to both healthy controls and individuals who developed headaches after receiving a vaccine. Interestingly, the elevated APP levels remained high even after six months, indicating a long-lasting effect of the COVID-19 infection on the brain.& lt;br />  
In contrast, while patients who experienced headaches following vaccination also showed some elevation in APP, their levels were not as high as those in the post-COVID-19 group. This suggests that the mechanism behind post-COVID-19 headaches may differ slightly from those caused by vaccines, although both appear to involve changes in amyloid processing.
 
The Role of Other Proteins
In addition to APP, the study also looked at other proteins that could be involved in the development of persistent headaches. Pregnancy Zone Protein (PZP), for example, was found to be elevated in both the post-COVID-19 and post-vaccination groups. PZP is an immune-suppressive protein that has been linked to various inflammatory conditions. Its elevation in patients with persistent headaches suggests that inflammation could play a role in the development of these symptoms.
 
Cathepsin L1 (CTSL), another protein measured in the study, was found to be elevated only in patients with post-COVID-19 headaches, and only at the beginning of the study. This indicates that CTSL may be more directly related to the initial phase of COVID-19 infection, rather than long-term symptoms.

Interestingly, Serum Amyloid A (SAA1), a protein that typically indicates inflammation, did not show any significant differences between the headache groups and the healthy controls. This suggests that while inflammation may be involved in the development of headaches, it is not the sole cause.
 
Understanding the Implications: A New Mechanism for Headache Development?
The findings of this study suggest a potential mechanism by which COVID-19 and its vaccines could cause long-lasting headaches. Amyloid Precursor Protein (APP), which is usually associated with neurodegenerative diseases like Alzheimer's, appears to play a role in the development of these headaches, particularly in those who have recovered from COVID-19.
 
One hypothesis is that the virus may increase the expression of APP in the brain, possibly through interactions with the ACE2 receptor, which the virus uses to enter cells. This could lead to an accumulation of APP, which in turn promotes inflammation and neurotoxic effects in the brain. Over time, this could manifest as persistent headaches, particularly in individuals who are already prone to headaches or have other underlying conditions.
 
For those who develop headaches after vaccination, the mechanism may be slightly different. The elevation in Pregnancy Zone Protein (PZP) suggests that the immune system’s response to the vaccine may trigger inflammation, leading to headaches in some individuals. However, since APP levels are not as high in the vaccine group, it is possible that the vaccine does not promote the same degree of amyloid processing changes as the virus itself.
 
Conclusion: What Does This Mean for Patients and the Medical Community?
The study conducted by researchers from Oslo University Hospital and other institutions provides valuable insights into the biological mechanisms behind post-COVID-19 and vaccine-related headaches. By identifying the involvement of proteins like Amyloid Precursor Protein (APP) and Pregnancy Zone Protein (PZP), the research points to a potential link between these headaches and amyloid processing in the brain.
 
While more research is needed to fully understand the implications of these findings, they offer a promising direction for future studies. One possibility is that treatments targeting amyloid processing or inflammation could be developed to help alleviate or prevent persistent headaches in patients who have recovered from COVID-19 or received a vaccine.
 
For now, individuals who are experiencing long-lasting headaches after COVID-19 or vaccination should consult with their healthcare providers. As researchers continue to investigate the underlying causes of these headaches, new treatment options may become available that can help reduce the burden of these debilitating symptoms.
 
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.medrxiv.org/content/10.1101/2024.10.19.24315794v1
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/stop-treating-headaches-lightly-as-covid-19-can-cause-increased-intracranial-brain-pressure-which-can-be-dangerous
 
https://www.thailandmedical.news/news/covid-19-news-magnetic-resonance-spectroscopy-shows-altered-metabolites-in-the-periaqueductal-gray-region-of-covid-19-individuals-with-headaches